Research in Allergic Rhinitis
Research in Allergic Rhinitis
Omalizumab reduces the risk of anaphylaxis in patients who are receiving immunotherapy. SLIT has been suggested to bring about a significant reduction in symptoms.
New and better new immune-based therapies are being searched for. Drugs called Anti-immunoglobulin E Antibodies (Omalizumab) have been evaluated in the treatment of Seasonal Allergic Rhinitis (SAR). Omalizumab reduces the risk of anaphylaxis in patients who are receiving immunotherapy. It is however expensive. Novel Forms of Immunotherapy that are associated with lower risk for fatal body reactions (anaphylaxis) are also being developed. Sublingually administered allergen immunotherapy (SLIT) has been suggested to bring about a significant reduction in symptom and medication scores in patients with allergic rhinitis.
References:
- Cecil Medicine, 23rd Ed.
- The Merck Manual, 18th Ed.
Cite this Article ⇣⇡
Please use one of the following formats to cite this article in your essay, paper or report:
-
APA
Dr. Nithin Jayan. (2014, June 03). Research in Allergic Rhinitis. Medindia. Retrieved on Jan 03, 2025 from https://www.medindia.net/health/conditions/allergic-rhinitis-research.htm.
MLA
Dr. Nithin Jayan. "Research in Allergic Rhinitis". Medindia. Jan 03, 2025. <https://www.medindia.net/health/conditions/allergic-rhinitis-research.htm>.
Chicago
Dr. Nithin Jayan. "Research in Allergic Rhinitis". Medindia. https://www.medindia.net/health/conditions/allergic-rhinitis-research.htm. (accessed Jan 03, 2025).
Harvard
Dr. Nithin Jayan. 2014. Research in Allergic Rhinitis. Medindia, viewed Jan 03, 2025, https://www.medindia.net/health/conditions/allergic-rhinitis-research.htm.